Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,272 total articles

Weatherford Announces Second-Quarter 2026 Conference Call

Weatherford Announces Second-Quarter 2026 Conference Call

Weatherford International plc has scheduled a conference call for July 22, 2026, to discuss its financial and operational results for the second quarter ended June 30, 2026. The company provided information about how investors can access the live webcast, participate via phone, and listen to a replay of the call. Weatherford is a global energy serv…

Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026

Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026

Nyxoah SA announced an extraordinary shareholders' meeting scheduled for July 9, 2026, to discuss and vote on the renewal of the board of directors' authorization to increase the company's share capital within the authorized capital framework for the next five years. The meeting will offer both in-person and video conference attendance options and …

SPX Technologies Announces Leadership Transition in D&M Segment

SPX Technologies Announces Leadership Transition in D&M Segment

SPX Technologies disclosed a planned leadership change within its Detection & Measurement segment. John Swann will retire in January 2027 after a successful tenure, and Eric Kaled, with a strong track record at SPX, will assume the role on August 31, 2026. The transition is part of a thoughtful succession plan aiming to maintain segment momentum.

XAI Floating Rate & Alternative Income Trust and XAI CLO & Income Opportunities Fund to Host Webinar Covering Important Fund Updates

XAI Floating Rate & Alternative Income Trust and XAI CLO & Income Opportunities Fund to Host Webinar Covering Important Fund Updates

XAI Floating Rate & Alternative Income Trust (XFLT) and XAI CLO & Income Opportunities Fund (OCTIX) will host a webinar on June 30, 2026 to review proposed sub-advisory agreements with King Street Capital Management and discuss potential benefits for shareholders. The Boards of Trustees have unanimously approved the King Street Sub-Advisory Agreeme…

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

uniQure reported initial six-month data from the Phase I/IIa trial of AMT-260 gene therapy in six patients with refractory mesial temporal lobe epilepsy. The therapy was generally well-tolerated with no serious adverse events, and half the patients experienced significant reductions in seizure frequency, indicating early biological activity. A high…

Sysco Canada Celebrates 26-Year Partnership With Second Harvest, Surpassing One Million Meals Donated

Sysco Canada Celebrates 26-Year Partnership With Second Harvest, Surpassing One Million Meals Donated

Sysco Canada announces a $50,000 donation to Second Harvest, reinforcing a 26-year partnership that has provided over one million meals and 1.34 million pounds of food to communities across Canada. The initiative supports food security and waste reduction through the Nourishing Neighbours program and focuses on vulnerable Northern and remote commun…

Aura Minerals Announces Repurchase Programs

Aura Minerals Announces Repurchase Programs

Aura Minerals Inc. has announced that its Board approved repurchase programs authorizing up to $200 million to buy back common shares and Brazilian Depositary Receipts over a one-year period. Funded by existing cash, the program aims to return capital to shareholders, optimize the company's capital structure, and reinforce confidence in its operati…

SL Science Holding Limited Reports Full Year 2025 Financial Results

SL Science Holding Limited Reports Full Year 2025 Financial Results

SL Science Holding Limited, a Taiwan-based biomedical company focused on innovative cellular and gene therapies, reported a 35% decline in 2025 revenue due to a strategic shift from retail to corporate wholesale distribution. Despite increased operating expenses and net losses, the company completed a Nasdaq listing through a business combination a…

Alamos Gold Provides Operational Update Across Canadian Operations

Alamos Gold Provides Operational Update Across Canadian Operations

Alamos Gold Inc. reported operational challenges at its Young-Davidson mine in Canada due to two seismic events and power outages, leading to damaged infrastructure, lower mining rates, and reduced production in Q2 2026. The company has revised downward its Q2 production guidance and anticipates full-year consolidated production will fall below gui…

Teva Releases Q2 2026 Aide Memoire

Teva Releases Q2 2026 Aide Memoire

Teva Pharmaceutical Industries Ltd. has released its Q2 2026 Aide Memoire to assist investors ahead of its upcoming second quarter earnings report, scheduled for July 29, 2026. The document consolidates previously shared public information including past results and management's outlook. Teva continues its transformation into a leading innovative b…

Churchill Downs Incorporated Announces State of Maryland’s Decision to Acquire the Preakness IP Rights

Churchill Downs Incorporated Announces State of Maryland’s Decision to Acquire the Preakness IP Rights

Churchill Downs Incorporated announced that the State of Maryland has decided to exercise its rights to acquire the intellectual property rights of the Preakness Stakes and Black-Eyed Susan Stakes by matching Churchill Downs' purchase agreement. While Churchill Downs had planned to acquire these rights for $85 million, the State's action prevents t…

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Teva Pharmaceutical Industries has submitted a New Drug Application (NDA) to the FDA for ecopipam, a first-in-class investigational therapy targeted at pediatric Tourette syndrome. The NDA submission follows positive Phase 3 clinical trial results showing ecopipam significantly delays relapse in pediatric patients and is generally well tolerated. E…